Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports.
Chimerix Inc. (NASDAQ: CMRX) shares surged 18.17 percent to close at $24.58 a share Wednesday. The stock traded between $21.56 and $24.90 on volume of 1.29 million shares traded. The company announced that it has reached an agreement with the FDA to initiate a pilot trial of brincidofovir for the treatment of adenovirus infections in immunocompromised patients. Shares of Chimerix are up approximately 60.0 percent year-to-date.
Get more information on Chimerix and free access to the in-depth equity report at: www.FiveStarEquities.com/CMRX
Infinera Corp. (NASDAQ: INFN) shares spiked 14.91 percent to close at $9.71 a share Wednesday. The stock traded between $8.83 and $9.75 on volume 5.59 million shares traded. Goldman Sachs has upgraded its rating on the company to “buy” from “neutral” and has set a price target of $11.50 on the stock. Shares of Infinera are down approximately 1.0 percent year-to-date.
Get more information on Infinera and free access to the in-depth equity report at: www.FiveStarEquities.com/INFN
Rite Aid Corporation (NYSE: RAD) shares gained 7.45 percent to close at $6.92 a share Wednesday. The stock traded between $6.59 and $6.95 on volume of 35.51 million shares traded. Goldman Sachs has upgraded its rating on the company to “buy” and has also raised its price target to $8.00 from $5.00. Shares of Rite Aid are up approximately 36.0 percent year-to-date.
Get more information on Rite Aid and free access to the in-depth equity report at: www.FiveStarEquities.com/RAD
Intrexon Corp. (NYSE: XON) shares jumped 11.46 percent to close at $30.55 a share Wednesday. The stock traded between $27.03 and $31.24 on volume 1.27 million shares traded. The company announced that it has formed an Exclusive Channel Collaboration with Amneal Pharmaceuticals LLC, the 7th largest generic drug manufacturer in the U.S. Shares of Intrexon are up approximately 28.0 percent year-to-date.
Get more information on Intrexon free access to the in-depth equity report at: www.FiveStarEquities.com/XON
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Five Star Equities has no financial relationship with any company whose stock is mentioned in this release.
Contact: Five Star Equities [email protected]